+1 (202) 780-3397
Short Communication - Asian Journal of Biomedical and Pharmaceutical Sciences (2021) Volume 11, Issue 82
Heparin treatment in COVID-19: Where are we?
Coronavirus disease 2019 (COVID-19) is a severe acute respiratory syndrome with a high mortality rate; it is caused by SARS-CoV-2, a new virus of the Corona viridae family that emerged in Wuhan, Hubei, China, in December 2019 and rapidly spread worldwide until declared by the World Health Organization a global pandemic on March. The race for an effective drug to prevent or treat SARS- CoV-2 infection is the highest priority among health care providers, government officials, and the pharmaceutical industry. Despite scientific effort, no pharmacological intervention has proven definitively beneficial, and care is primarily supportive.
Author(s): Manuela Rizzo Antonio Pisani *